COVID-19 Vaccines and Vaccination
A section of Vaccines (ISSN 2076-393X).
Section Information
Aims
The aim of this “COVID-19 Vaccines and Vaccination” is to provide with information on currently available and novel experimental approaches for the development of vaccines for the control of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and it associated coronavirus disease 2019 (COVID-19).
Scope
Global efforts to develop vaccines recently have resulted in 3 FDA-approved vaccines candidates with excellent safety and efficacy profiles in human clinical trials that have resulted in large-scale vaccination campaigns early in 2021.Currently, RNA-based vaccines and replication defective adenovirus-based vector have been used for the treatment of COVID-19 in humans. However, additional safe and effective vaccines are needed for the treatment of SARS-CoV-2 infection and its associated COVID-19 disease.
In this section “COVID-19 Vaccines and Vaccination” we will consider original research and review articles, including short reports and full-size manuscripts, covering aspects related to SARS-CoV-2 vaccine development for the treatment of COVID-19 disease. These include (but not limited to) antigen selection; subunit, inactivated, and live-attenuated vaccines; approaches to enhance innate and adaptive B- and T-cell protective responses; vaccine adjuvants; delivery methods and strategies; immunological responses to SARS-CoV-2 infection or COVID-19 disease; and animal models to assess protection efficacy against SARS-CoV-2 infection and COVID-19 disease.
Editorial Board
Special Issues
Following special issues within this section are currently open for submissions:
- Recent Research on Neutralizing Antibody Response to SARS-CoV-2 Variants (Deadline: 6 August 2025)
- 3rd Edition: Safety and Autoimmune Response to SARS-CoV-2 Vaccination (Deadline: 30 September 2025)
- COVID Vaccines: Design, Development, and Immune Response Studies: 2nd Edition (Deadline: 30 November 2025)
- Population Immunity and Persistence to SARS-CoV-2 Induced by Infection and Vaccination, Protection Against New Infections and Implication for Further Vaccination: 2nd Edition (Deadline: 30 November 2025)
- SARS-CoV-2: Infections, Treatment, and Development of Vaccines—2nd Edition (Deadline: 28 February 2026)
- Receptor-Binding Domain-Based Vaccines Against SARS-CoV-2 (Deadline: 28 February 2026)
- SARS-CoV-2 Infection and COVID-19 Vaccination: Exploring Pathogenesis, Immune Response and Immunopathogenic Complications (Deadline: 31 March 2026)
- Long-Term Immunity and Booster Strategies for COVID-19 Vaccines (Deadline: 31 March 2026)
- COVID-19 Vaccination and Public Health: Addressing Global, Regional and Within-Country Inequalities (Deadline: 30 April 2026)
- Exploring Cutaneous Autoimmune Disease Flares in the Wake of COVID-19 Infection and Vaccination (Deadline: 10 May 2026)
- SARS-CoV-2 Pathogenesis, Vaccines and Therapeutics (Deadline: 31 May 2026)
- Immunization of Immunosuppressed Patients (Deadline: 30 June 2026)
Topical Collections
Following topical collections within this section are currently open for submissions:
